Friday, 16 Feb 2018

You are here

One-Third of FDA Approvals Need Post-Marketing Safety Changes

One-third of newly approved drugs in the next decade will require new safety warnings based on pharmacovigilance, according to a new study in JAMA. (Citation Source: http://buff.ly/2r3dYUs)

An analysis by the Food and Drug Administration (FDA), looked at all 222 prescription drugs (183 pharmaceuticals and 39 biologics) approved between 2001 through 2010.

They identified 71 new drugs with 123 new postmarket safety events (3 withdrawals, 61 boxed warnings, and 59 safety communications) during a follow-up period of 11.7 years. The overall proportion drugs affected by a postmarket safety event at 10 years was 32%.  The median time from approval to first postmarket safety event was 4.2 years.

These events resulted in either black-box warnings and lesser alerts (warnings, cautions) for many of these drugs, with only 3 being withdrawn from th market (Bextra, Raptiva, Zelnorm).

These findings were significantly more frequent among biologics (incidence rate ratio [IRR] = 1.93), psychiatric agents, those drugs receiving accelerated approval and those with near–regulatory deadline approval. 

Post-marketing safety events were found in 32% of new drugs approved by the FDA from 2001 through 2010. Biologics, psychiatric therapeutics, and accelerated and near–regulatory deadline approval agents were at greater risk for new, evolvig safety events, suggesting an ongoing need for pharmacovigilance with new agents.

 

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

ACIP Guidelines on H. Zoster Vaccination Updated

The ACIP has discussed and analyzed its VZV vaccination policy to ensure safety and reduce disease burden. This report serves as a supplement to the 2008 Prevention of Herpes Zoster Recommendations.

Herpes zoster is a localized, usually painful, cutaneous eruption resulting from reactivation of latent varicella zoster virus (VZV). Herpes zoster is common: approximately one million cases occur each year in the United States.

Higher Fracture Risk with PMR and GCA

Corticosteroid therapy is integral to the treatment of polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) and a new retrospective cohort study from the UK shows that PMR and GCA have similar, increased risk of fractures.

Problems with Biologic Drug Storage

Is your patient’s refrigerator the problem with the inefficacy of biologic therapies? Studies show most patients don't store their biologics correctly, which may be a source of limited drug efficacy.

Prevention of HBV Infection: How Are We Doing?

In 2016 the WHO set out to eliminate HBV infection as a public health threat by 2030. So far, we are far from this goal as vaccine implementation has been suboptimal in a number of important patient populations, including patients with rheumatologic diseases, as well as other immunocompromising diseases like HIV.

B Cell Changes Predict Autoimmunity with Checkpoint Inhibitors

The Journal of Clinical Investigation reports results of a study showing that increases in CD21lo B cells and plasmablasts following that combination checkpoint blockade preceded the onset of immune-related adverse events.

While some have postulated that IRAEs are thought to be T cell mediated, B cells have also been implicated. Investigators studied 39 melanoma patients undergoing treatment with either anti-CTLA4 or anti-PD1, or combination CCB therapy. They analyzed changes in circulating B cells before and after the first cycle of therapy of immune checkpoint blockade (23 received combination therapy, 8 received anti-CTLA4, and 8 received anti-PD1).